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Synergistic Effects of a Combination of Low-Dose Basic
Fibroblast Growth Factor and Citicoline After Temporary
Experimental Focal Ischemia
Wolf R. Scha¨bitz, MD; Fuhai Li, MD; Katsumi Irie, MD; Bobby W. Sandage, Jr, PhD;
Kenneth W. Locke, PhD; Marc Fisher, MD
Background and Purpose—Basic fibroblast growth factor (bFGF) and citicoline (cytidine 59-diphosphate choline, an
endogenous compound that stabilizes membrane function) have demonstrated neuroprotective effects after focal
cerebral ischemia. Both agents are candidates for future stroke therapy in humans. For evaluation of synergistic effects
of bFGF and citicoline, a low-dose combination of both compounds was tested against each compound alone
and placebo.
Methods—Four groups of Sprague-Dawley rats (n512 per group) underwent 90 minutes of focal cerebral ischemia with
the use of the suture model of middle cerebral artery occlusion. Animals were randomly and blindly assigned to one of
the following treatment groups: placebo, low-dose citicoline (250 mg/kg IP daily for 4 days), low-dose bFGF (10 mg/kg
per hour IV for 3 hours), and the combination of both (250 mg/kg citicoline and 10 mg/kg per hour bFGF).
Triphenyltetrazolium chloride staining was used after 4 days to determine postmortem infarction. Neurological scores
were assessed on a daily basis.
Results—The premature mortality rate was 41.7% in the placebo and citicoline groups, 33.3% in the bFGF group, and 25%
(P5NS) in the combination group. The mean neurological score on day 4 was 3.161.6 (placebo), 3.161.6 (citicoline),
2.961.5 (bFGF), and 2.461.4 (combination) (P5NS). The mean volume of infarction was significantly reduced in the
combination group (136.5625.4 mm3) versus placebo (172.6648.9 mm3; P50.036, Fisher test), versus citicoline alone
(186.0635.7 mm3; P50.005, Fisher test), and versus bFGF alone (176.0649.2 mm3; P50.023, Fisher test).
Conclusions—These results demonstrate synergistic effects of a low-dose combination of the growth factor bFGF and
citicoline after temporary experimental focal cerebral ischemia and furthermore support the effectiveness of a
combination treatment regimen for the management of acute stroke. (Stroke. 1999;30:427-432.)
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Neuroprotective therapy is effective in animal strokemodels but remains unproven in clinical stroke. Neuro-
protective agents such as N-methyl-D-aspartate antagonists
are well tolerated in animals but may cause major side effects
in humans (eg, psychotic events). Reducing doses may reduce
side effects but may also lower the neuroprotective capability
of the agent. One way to reduce the dose of drugs and to
maintain, or even increase, neuroprotective effects is to use a
combination of agents that act on different steps in the
ischemic cascade. Recently, combination studies for the
treatment of experimental focal cerebral ischemia were re-
ported with encouraging results for the combination of
thrombolytic and neuroprotective therapy1–3 and 2 different
neuroprotective agents.4
An intriguing idea for the treatment of acute stroke is the
use of growth factors that have not only neuroprotective but
also regenerative and proliferative capacities. A promising
See Editorial Comment, page 431
growth factor for the treatment of acute focal cerebral
ischemia in stroke models is basic fibroblast growth factor
(bFGF), a 18-kDa polypeptide that mediates the differentia-
tion, survival, and regeneration of neuronal cells through
specific receptors.5 It has been shown in several in vivo
experiments in different species that bFGF has neuroprotec-
tive and regenerative capabilities when administered after
focal cerebral ischemia.6–13 Possible mechanisms of action
for bFGF include a direct neuroprotective effect and an effect
on cerebral blood flow (CBF) and cerebrovascular tone.8,14,15
Citicoline (cytidine 59-diphosphate choline), a naturally
occurring endogenous compound that serves as an interme-
diate in the synthesis of the membrane phosphatidylcholine,
is thought to have membrane-stabilizing functions and to
reduce free fatty acid formation during stroke.16,17 Citicoline
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reduces the size of infarction and improves the neurological
outcome in experimental models of focal cerebral ische-
mia.1,4,18,19 In clinical studies, treatment with citicoline im-
proved cognitive and behavioral function in patients with
memory deficits.20,21 After human stroke, treatment with
citicoline improved neurological outcome22–24 and reduced
ischemic lesion volume as demonstrated by diffusion-
weighted MRI.25
To study the effect of a combination of bFGF and citicoline
on focal cerebral ischemia seems rationale since both agents
act through different mechanisms and may therefore have a
synergistic effect. Furthermore, bFGF and citicoline are
currently under clinical investigation as candidates for future
stroke therapy. For the combination of both agents, we
purposely chose dose levels for each compound that were
unlikely to be effective alone after cerebral ischemia.4,12,18,26
In this study we investigated the treatment effect of citicoline
(250 mg/kg), bFGF (10 mg/kg per hour), and the combination
of both versus placebo using the suture occlusion model of
the middle cerebral artery (MCA). The aim of the study was
to determine whether the combination treatment had saluta-
tory effects on mortality, on neurological outcome, and, in
particular, on infarction.
Materials and Methods
In 48 male Sprague-Dawley rats, weighing 300 to 350 g, 90 minutes
of temporary focal cerebral ischemia was induced with the use of the
intraluminal suture occlusion method. Our procedures were ap-
proved by the Animal Research Committee of the University of
Massachusetts Medical School (Animal Research Committee Proto-
col No. 643). All experiments were performed in a blinded manner.
Nonfasted animals were randomly assigned before surgery to one of
the following groups: 12 animals treated with low-dose citicoline
(citicoline group), 12 animals treated with low-dose bFGF (bFGF
group), 12 animals treated with a combination of low-dose citicoline
and low-dose bFGF (combination group), and 12 animals treated
with placebo.
The animals were anesthetized intraperitoneally with 400 mg/kg
of chloral hydrate. The left femoral artery was cannulated with
PE-50 polyethylene tubing for continuous monitoring of arterial
blood pressure and blood sampling for analysis of blood gases.
Measurements were performed before surgery and 15, 105, and 195
minutes after ischemic onset. Rectal temperature was maintained
during surgery at 37°C with a feedback-regulated heating lamp. The
right MCA was occluded by the transvascular suture method as
previously described.18,27 For MCA occlusion, the right common
carotid artery and the right external carotid artery were exposed
through a midline neck incision. The distal common carotid artery
and the external carotid artery were first ligated with a 3-0 silk
suture. A 4-0 monofilament nylon suture (40 mm in length), whose
tip had been rounded by heating near a flame and then coated with
silicon (Bayer), was inserted through an arteriectomy of the common
carotid artery and gently advanced into the internal carotid artery.
Positioned '17 mm from the bifurcation, the tip of the suture
occluded unilaterally the proximal anterior cerebral artery, the
origins of the MCA, and the posterior communicating artery. To
prevent bleeding, the common carotid artery was loosely ligated with
a 3-0 silk suture just distal to the arteriotomy.
Intravenous infusion of the growth factor or vehicle was started 30
minutes after vessel occlusion and maintained for 3 hours; citicoline-
or placebo-treated animals received vehicle (1% BSA in physiolog-
ical saline), and bFGF-treated animals (bFGF and combination
groups) received 10 mg bFGF per kilogram per hour in 1% BSA in
physiological saline. After reperfusion, animals were treated with an
intraperitoneal bolus of citicoline 250 mg/kg in physiological saline
(citicoline and combinations groups) or with the vehicle alone (bFGF
and placebo groups). At the conclusion of the intravenous infusion,
the animals were allowed to recover from the anesthesia and were
scored neurologically according to a 6-point scale: 05no neurolog-
ical deficit, 15failure to extend left forepaw fully, 25circling to the
left, 35falling to the left, 45no spontaneous walking with a
depressed level of consciousness, and 55death.27 Animals that died
within 12 hours of vessel occlusion were not included in the study.
During the next 3 days the animals had free access to food and
water. The neurological examination and the intraperitoneal treat-
ment with citicoline or vehicle were performed in all animals on a
daily basis. On the fourth day the animals were killed with an
overdose of chloral hydrate (administered intraperitoneally) and
decapitated. The brains were removed and inspected for subarach-
noid hemorrhage. Animals with subarachnoid hemorrhage were
excluded from the study. The brains then were frozen at 220°C and
coronally sectioned into six 2-mm-thick slices. The brain slices were
incubated for 30 minutes in a 2% solution of 2,3,5-triphenyltetrazo-
lium chloride (TTC) at 37°C and then fixed by immersion in a 10%
buffered formalin solution. TTC stains normal brain tissue red, while
ischemic tissue turns white.28,29 For quantification of infarct vol-
umes, the brain slices were photographed with a charge-coupled
device camera (EDC-1000HR Computer Camera, Electrim Corpo-
ration), and image analysis was performed on a personal computer
with a commercially available image analysis program (Bio Scan,
Optomas). To compensate for the effect of brain edema, the
corrected infarct volume was calculated by the following formula:
corrected infarct area equals left hemisphere area minus (right
hemisphere area minus infarct area).30,31 The infarcted area was
calculated separately for cortical and subcortical regions. The cor-
rected mean total infarct volume and cortical and subcortical infarct
volumes then were calculated by multiplying the respective corrected
infarct areas by slice thickness. The brains of animals that died
prematurely after $12 hours after occlusion were harvested within 8
hours and evaluated in a manner similar to that used for those who
were electively killed.29
Values presented in this study are expressed as mean6SD. After
acquisition of all data, the randomization code was broken. ANOVA
and subsequent post hoc Fisher protected least significant difference
test were used to determine the statistical significance of differences
in physiological variables and volumes of infarction among all 4
groups. The Kruskal-Wallis test was performed for nonparametric
variables such as mortality rate and neurological score. A P value
,0.05 was considered statistically significant.
Results
Physiological variables, presented in Table 1, showed no
significant differences when all 4 groups were compared. The
percent body weight decline for the surviving animals in the
placebo, citicoline, bFGF, and combination groups was 17%,
16%, 18.5%, and 16.8%, respectively (P5NS). In the placebo
and citicoline groups, 5 of 12 animals died between 24 and 96
hours after ischemia; thus, the premature mortality rate in
both groups was 41.7%. Four of 12 animals died in the bFGF
group, 24 to 96 hours after ischemia; the mortality rate was
33.3%. Premature death occurred in only 3 of 12 animals in
the combination treatment group; the mortality rate in this
group was 25% (P5NS). The mean neurological score for the
daily examinations was not statistically significantly different
among the 4 groups (Table 2).
The mean volume of infarction was 172.6648.9 mm3 in
the placebo group, 186.0635.7 mm3 in the low-dose citico-
line alone group, 176.0649.2 mm3 in the low-dose bFGF
alone group, and 136.5625.4 mm3 in the combination treat-
ment group (Figure 1). The difference of the mean values of
infarct volume was significant for the combination group
versus the controls (P50.036, Fisher test), versus the
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citicoline-treated group (P50.005, Fisher test), and versus
the bFGF-treated group (P50.023, Fisher test). The sub-
cortical infarct volume was 66.5618.3 mm3 in the placebo
group, 66.2615.8 mm3 in the citicoline-treated group,
69.5618.1 mm3 in the bFGF-treated group, and
48.6611.2 mm3 in the combination-treated group (Figure
2); the difference was significant for the combination
versus the placebo, citicoline, and bFGF groups (P50.009,
P50.01, and P50.003, respectively; Fisher test). The
cortical infarct volume was 106.1634.1 mm3 in the pla-
cebo group, 119.7622.2 mm3 in the citicoline-treated
group, 106.5638.1 mm3 in the bFGF-treated group, and
87.4624.9 mm3 in the combination-treated group (P5NS)
(Figure 2).
Discussion
The results of this study demonstrate to our knowledge for the
first time that a low-dose combination of a growth factor
(bFGF) and a neuroprotectant (citicoline) significantly re-
duces infarct volume after temporary focal cerebral ischemia.
The reduction in infarct volume produced by the combination
therapy versus placebo was 22% (Figure 1). The reduction
was more effective in subcortical than in cortical areas of
infarction (Figure 2). There was no treatment effect for either
of the 2 compounds alone, nor were there significant side
effects at the low doses used in this study. In particular, no
significant decrease of blood pressure occurred in the bFGF-
treated groups, since the chosen dose was below the reported
hypotensive dose of 60 mg/kg per hour.12,32 No significant
difference in weight loss, which is a known side effect after
bFGF treatment, was observed among the groups during the
experiment.10
The neuroprotective effects of bFGF and citicoline after
experimental focal cerebral ischemia are well documented
and include infarct reduction and improved neurological and
behavioral outcome.1,4,8,12,18,19 Some of these studies demon-
strated a dramatic neuroprotective effect with infarct reduc-
tions up to 50%.12,18 However, the doses used in these single
TABLE 1. Physiological Parameters for All Groups at Baseline and 15, 105, and
195 Minutes After MCA Occlusion
Group
Placebo Citicoline bFGF Combination
Baseline
pH 7.4160.05 7.4160.07 7.4260.05 7.3860.08
PCO2, mm Hg 38.264.2 36.763.0 32.667.6 39.365.8
PO2, mm Hg 102.4613.7 90.369.7 92.565.4 88.868.2
MABP, mm Hg 93.568.5 90.569.5 94.466.9 102.5611.3
Body temperature, °C 37.060.2 36.960.2 37.160.1 37.060.1
15 min after MCAO
pH 7.3960.05 7.3460.09 7.4260.10 7.3760.08
PCO2, mm Hg 33.566.7 43.069.2 34.265.4 42.464.9
PO2, mm Hg 94.8610.1 80.4613.8 91.768.1 87.869.2
MABP, mm Hg 84.564.1 83.565.5 88.362.9 90.567.3
Body temperature, °C 37.260.2 37.060.4 37.260.1 37.160.1
105 min after MCAO
pH 7.3660.03 7.3360.05 7.3560.03 7.3760.07
PCO2, mm Hg 33.267.3 42.164.9 33.168.8 36.266.1
PO2, mm Hg 89.969.6 79.166.2 85.169.8 85.7611
MABP, mm Hg 87.5614.6 90.567.9 82.468.9 77613.9
Body temperature, °C 36.960.1 37.060.3 37.060.1 37.060.1
195 min after MCAO
pH 7.3460.04 7.3360.07 7.3360.10 7.3560.03
PCO2, mm Hg 34.3610.4 42.265.2 35.067.6 40.164.2
PO2, mm Hg 91.964.6 82.0610.9 84.367 87.568.7
MABP, mm Hg 98.566.6 101.568.8 89.769.5 87.5614.6
Body temperature, °C 37.060.1 36.860.1 37.160.2 37.160.2
Values are mean6SD. MCAO indicates MCA occlusion. Differences in physiological parameters
among groups were not statistically significant (P.0.05, ANOVA).
TABLE 2. Neurological Scores
Group Day 2 Day 3 Day 4
Placebo 2.361.0 2.961.5 3.161.6
Citicoline 2.561.1 3.061.5 3.161.6
bFGF 2.461.2 2.861.4 2.961.5
Combination 1.861.1 2.361.3 2.461.4
Values are mean6SD. Differences among groups were not statistically
significant (P.0.05, Kruskal-Wallis test).
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compound studies with systemic administration were much
higher than the ones we used for this experiment (500 mg/kg
citicoline versus 250 mg/kg and 45 mg/kg per hour of bFGF
versus 10 mg/kg per hour). To study possible synergy
between citicoline and bFGF, the dosage level for each
individual compound was purposely chosen on the basis of
doses previously demonstrated not to be neuroprotective1,4 or
empirically chosen below their reported neuroprotective effi-
ciency.12,26 We confirm here that 250 mg/kg of citicoline and
10 mg/kg per hour of bFGF are not neuroprotective doses in
this model of temporary focal cerebral ischemia. However, a
combination of the same doses was able to achieve a
significant neuroprotective effect versus placebo and each
drug alone without producing any side effects. The explora-
tion of the effectiveness of combination therapies for stroke
seems rational since cerebral ischemia triggers a multitude of
pathophysiological and biochemical events that affect the
evolution of focal ischemic injury differently. Impeding
different steps in the ischemic cascade with different thera-
peutic agents may not only synergistically enhance the
neuroprotective effect but may also allow the use of lower
doses of each drug and consecutively reduce side effects. This
approach has been demonstrated to be promising in prior
experimental studies1–4,19 and may serve as a future strategy
for stroke therapy in humans. The combination of citicoline
and bFGF is of special interest because both agents are
currently under investigation in clinical trials and may be
available for human stroke therapy in the near future.
Potential bFGF-mediated mechanisms that contribute to
the reduction in infarct size may be direct protective effects
on neurons, glia, and cerebral endothelial cells and positive
effects on cerebrovascular tone and CBF.8,12–15,33–36 bFGF
protects neurons in vitro against a number of insults that play
crucial roles in the pathophysiology of ischemia such as
anoxia, hypoglycemia, excitatory amino acids, Ca21 iono-
phores, free radicals, and nitric oxide.14,33–36 Moreover, the
neuroprotective action of bFGF may depend on neuronal
gene transcription and protein synthesis, particularly at the
margins of focal infarcts.12,33 Another possible mechanism of
bFGF-induced reduction in infarct size is through the regu-
lation of cerebrovascular tone and CBF. Topical application
of bFGF dilates pial cerebral arteries in rats,15 increases
regional blood flow, and may increase the blood supply to the
compromised penumbral regions of focal cerebral ischemia.8
However, no effect on CBF was found in a cat model of focal
cerebral ischemia.13
Mechanisms for citicoline-mediated neuroprotection in-
clude membrane stabilization and restoration. In the normal
synthetic process, the enzyme cholinephosphotransferase cat-
alyzes the reaction of citicoline with diacylglycerol to pro-
duce phosphatidylcholine and cytidine-59-monophosphate
(CMP).16,17 After an ischemic event, ATP-dependent removal
of CMP is impaired, and increased CMP concentrations
reverse the normal cholinephosphotransferase reaction to
yield diglycerides and cytidine 59-diphosphate choline.37 The
very active diglyceride lipase rapidly degrades the accumu-
lated diglycerides to free fatty acids.38,39 Accumulated free
fatty acids are converted to oxygenated metabolites through
the cyclooxygenase and lipooxygenase pathways, and these
products are involved in ischemia-associated edema and
inflammation.40 Restoration of the cholinephosphotransferase
reaction by citicoline prevents the release of free fatty acids
during ischemia and helps to remove diacylglycerol by
channeling it into phosphatidylcholine.16,17
In conclusion, our present findings suggest that a low-dose
combination of the growth factor bFGF and citicoline is safe
and reduces infarct volume after temporary experimental
focal cerebral ischemia. This result may encourage further
studies combining the unique capabilities of growth factors
with other neuroprotectants or thrombolysis. Since bFGF and
citicoline are already under clinical investigation, it may be
rational to explore combination therapy with both agents in
human stroke.
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Figure 1. Mean infarct volumes. Data are mean6SD. P indi-
cates placebo; C, citicoline group; F, bFGF group; and CF,
combination group. *The difference of the mean infarct volume
was statistically significant for CF versus P, C, and F (P,0.05,
Fisher test).
Figure 2. Cortical and subcortical infarct volumes. Data are
mean6SD. P indicates placebo; C, citicoline group; F, bFGF
group; and CF, combination group *The difference of the sub-
cortical infarct volume was statistically significant for CF versus
P, C, and F (P,0.05, Fisher test).
430 bFGF and Citicoline in Focal Ischemia
 at UNIV MASSACHUSETTS on March 27, 2009 stroke.ahajournals.orgDownloaded from 
References
1. Andersen M, Meden P, Overgaard K, Boysen G. Effects of citicoline
combined therapy in a rat embolic stroke model. Stroke. 1998;29:
279. Abstract.
2. Zivin JA, Mazzarella V. Tissue plasminogen activator plus glutamate
antagonist improves outcome after embolic stroke. Arch Neurol. 1991;
48:1235–1238.
3. Meden P, Overgaard K, Sereghy T, Boysen G. Enhancing the efficacy of
thrombolysis by AMPA receptor blockade with NBQX in a rat embolic
stroke model. J Neurol Sci. 1993;119:209–216.
4. O¨ nal MZ, Li F, Tatlisumak T, Locke KW, Sandage BW Jr, Fisher M.
Synergistic effects of citicoline and MK-801 in temporary experimental
focal ischemia in rats. Stroke. 1997;28:1060–1065.
5. Wagner JA. The fibroblast growth factors: an emerging family of neural
growth factors. Curr Top Microbiol Immunol. 1991;165:95–118.
6. Nozaki K, Finklestein SP, Beal MF. Basic fibroblast growth factor
protects against hypoxia-ischemia and NMDA-neurotoxicity in neonatal
rats. J Cereb Blood Flow Metab. 1993;13:221–228.
7. Nozaki K, Finklestein SP, Beal MF. Delayed administration of basic
fibroblast growth factor protects against NMDA neurotoxicity in neonatal
rats. Eur J Pharmacol. 1993;232:295–297.
8. Tanaka R, Miyasaka Y, Yada K, Ohwada T, Kameya T. Basic fibroblast
growth factor increases regional blood flow and reduces infarct size after
experimental ischemia in a rat model. Stroke. 1995;26:2154–2159.
9. Ren JM, Finklestein SP. Time window of infarct reduction by intravenous
basic fibroblast growth factor in focal cerebral ischemia. Eur
J Pharmacol. 1997;327:11–16.
10. Kawamata T, Alexis NE, Dietrich WD, Finklestein SP. Intracisternal
basic fibroblast growth factor enhances behavioral recovery following
focal cerebral ischemia in the rat. J Cereb Blood Flow Metab. 1996;16:
542–547.
11. Jiang N, Finklestein SP, Do T, Caday CG, Charette M, Chopp M.
Delayed intravenous administration of basic fibroblast growth factor
reduces infarct volume in a model of focal cerebral ischemia and reper-
fusion in the rat. J Neurol Sci. 1996;139:173–179.
12. Fisher M, Meadows M-E, Do T, Weise J, Trubetskoy V, Charette M,
Finklestein SP. Delayed treatment with intravenous basic fibroblast
growth factor reduces infarct size following permanent focal cerebral
ischemia in rats. J Cereb Blood Flow Metab. 1995;15:953–959.
13. Bethel A, Kirsch JR, Koehler RC, Finklestein SP, Traystman RJ. Intra-
venous basic fibroblast growth factor decreases brain injury resulting
from focal ischemia in cats. Stroke. 1997;28:609–615.
14. Mattson MP, Scheff SW. Endogenous neuroprotection factors and
traumatic brain injury: mechanisms of action and implications for
therapy. J Neurotrauma. 1994;11:3–33.
15. Rosenblatt S, Irikura K, Caday CG, Finklestein SP, Moskowitz MA.
Basic fibroblast growth factor dilates rat pial arterioles. J Cereb Blood
Flow Metab. 1994;14:70–74.
16. Kennedy EP, Weiss SB. The function of cytidine coenzymes in the
biosynthesis of phospholipids. J Biol Chem. 1956;222:193–214.
17. Weiss GB. Metabolism and actions of CDP-choline as an endogenous
compound and administered exogenously as citicoline. Life Sci. 1995;56:
637–660.
18. Scha¨bitz W-R, Weber J, Takano K, Sandage BW, Locke KW, Fisher M.
The effects of prolonged treatment with citicoline in temporary experi-
mental focal ischemia. J Neurol Sci. 1996;138:21–25.
19. Aronowski J, Strong R, Grotta JC. Citicoline for treatment of experi-
mental focal ischemia: histologic and behavioral outcome. Neurol Res.
1996;18:570–574.
20. Spiers PA, Myers D, Hochanadel GS, Liebermann HR, Wurtman RJ.
Citicoline improves verbal memory in aging. Arch Neurol. 1996;53:
441–448.
21. Alvarez XA, Laredo M, Corzo D, Fernandez-Novoa L, Mouzo R, Perea
JE, Daniele D, Cacabelos R. Citicoline improves memory performance in
elderly subjects. Methods Find Exp Clin Pharmacol. 1997;19:201–210.
22. Tazaki Y, Sakai F, Otomo E, Kutsuzawa T, Kameyama M, Omae T,
Fujishima M, Sakuma A. Treatment of acute cerebral infarction with a
choline precursor in a multicenter double-blind placebo-controlled study.
Stroke. 1988;19:211–216.
23. Hazama T, Hasegawa T, Ueda S, Sakuma A. Evaluation of the effect of
citicoline on poststroke hemiplegia employing a double-blind controlled
trial. J Neurosci. 1980;11:211–225.
24. Bruhwyler J, Vandorpe J, Geczy J. Multicentric open label study of the
efficacy and tolerability of citicoline in the treatment of acute cerebral
infarction. Curr Ther Res Clin Exp. 1997;58:309–316.
25. Warach S, Benfield A, Schlaug G. Reduction of lesion volume in human
stroke by citicoline detected by diffusion-weighted magnetic resonance
imaging: a pilot study. Ann Neurol. 1996;40:527–528.
26. Tatlisumak T, Takano K, Carano RAD, Fisher M. Effect of basic
fibroblast growth factor on experimental focal ischemia studied by
diffusion-weighted and perfusion imaging. Stroke. 1996;27:2292–2298.
27. Zea Longa E, Weinstein PR, Carlson S, Cummins R. Reversible middle
cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:
84–91.
28. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL,
Bartkowski HM. Evaluation of 2,3,5-triphenyltetrazolium chloride as a
stain for detection and quantification of experimental cerebral infarction
in rats. Stroke. 1986;17:1304–1308.
29. Li F, Irie K, Anwer MS, Fisher M. Delayed triphenyltetrazolium chloride
staining remains useful for evaluating cerebral infarct volume in a rat
stroke model. J Cereb Blood Flow Metab. 1997;17:1132–1135.
30. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp
FR. A semiautomated method for measuring brain infarct volume.
J Cereb Blood Flow Metab. 1990;10:290–293.
31. Lin T-N, He YY, Wu G, Khan M, Hsu CY. Effect of brain edema on
infarct volume in a focal ischemia model in rats. Stroke. 1993;24:
117–121.
32. Cuevas P, Carceller F, Ortega S, Zazo M, Nieto I, Gimenez-Gallego G.
Hypotensive activity of basic fibroblast growth factor. Science. 1991;254:
1208–1210.
33. Mattson MP, Murrain M, Guthrie PB, Kater SB. Fibroblast growth factor
and glutamate: opposing roles in the generation and degeneration of
hippocampal neuroarchitecture. J Neurosci. 1989;9:3728–3740.
34. Finklestein SP, Kemmou A, Caday CG, Berlove DJ. Basic fibroblast
growth factor protects cerebrocortical neurons against excitatory amino
acid toxicity in vitro. Stroke. 1993;24(suppl I):I-41–I-43.
35. Freese A, Finklestein SP, DiFiglia M. Basic fibroblast growth factor
protects striatal neurons in vitro from NMDA-receptor mediated excito-
toxicity. Brain Res. 1992;575:351–355.
36. Maiese K, Boniece I, DeMeo D, Wagner JA, Peptide growth factors
protect against ischemia by preventing nitric oxide toxicity. J Neurosci.
1993;13:3034–3040.
37. Goracci G, Francescangeli E, Horrocks LA, Porcellati G. The reverse
reactions of cholinephosphotransferase in rat brain microsomes: a new
pathway for degradation of phosphatidylcholine. Biochim Biophys Acta.
1981;664:373–379.
38. Lopez G-Coviella IL, Wurtman R. Enhancement by cytidine of
membrane phospholipid synthesis. J Neurochem. 1992;59:338–343.
39. Porcellati G, DeMedio GF, Fini C, Floridi A, Goracci G, Horrocks LA,
Lazarewicz JW, Palmerini CA, Strosznaider J, Trovarelli G. Phospholipid
and its metabolism in ischemia. Proc Eur Soc Neurochem. 1978;1:
285–302.
40. Galli C, Spagnuolo C, Sautebin L, Galli G. Arachidonic acid metabolism
and cyclic nucleotides in the CNS during hypoxia. In: Neuhoff V, ed.
Proceedings of the European Society for Neurochemistry. Vol 1.
Weinheim, Germany: Verlag Chemie Weinheim; 1978:271–284.
Editorial Comment
As many readers are well aware, rarely does a single
therapeutic agent provide truly impressive neuroprotection in
experimental stroke. Because the list of cellular and molec-
ular actors in ischemic injury is voluminous, there is an
increasing need for solid investigations of mechanistically
driven, combination therapy. The accompanying article uses
just such an approach and offers the important observation
that low doses of bFGF and citicoline can synergistically
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improve tissue injury in a standard rodent model of focal
cerebral ischemia. Abundant literature demonstrates that
many members of the growth factor families are neuropro-
tective and regenerative in experiental brain injury, although
efficacy in human stroke and cerebral ischemia remains
unclear. Citicoline, in contrast, has been shown to be useful in
cognitively impaired patients and to improve functional
outcomes in acute stroke.1,2 The compound’s mechanism(s) is
not straightforward and is often placed under the broad
umbrella of “membrane stabilization.”
The practical rationale for combination therapy includes
(1) the ability to target an outcome level that is greater than
can be achieved with either agent alone, whether additive or
synergistic, or (2) the reduction of individual agent dosages
with consequent reduction of undesirable side effects or
toxicity. In the study of Scha¨bitz et al, the authors deliberately
chose doses of each agent for that were lower relative to their
previous studies, and therefore potentially suboptimal, with
the goal of avoiding complications such as hypotension. This
strategy did allow the demonstration of a positive experimen-
tal result. Furthermore, it underscores the need for a thought-
ful study design with clear rationale and knowledge of each
compound’s dose-response relationships if a combined ther-
apy investigation is to be successful. It should be noted that
CBF and brain temperature were not measured in the various
treatment groups. The apparent rationale was that these
variables had been previously examined in studies using
higher doses of a single agent, and no flow or temperature
effects were noted. Nevertheless, it can be difficult to predict
the effect of combined therapy on key physiological param-
eters from historical data based on a single agent.
It should also be noted that histological protection was
limited to subcortical brain regions. Presumably citicoline
acts on all cells, and bFGF is not known for cell selectivity in
neuronal rescue. Because infarction was determined by TTC
staining, the authors appropriately do not speculate on re-
gional or cellular heterogenity in the synergism of citicoline
and bFGF. However, further work will be important to
differentiate the target cells or even potential gray versus
white matter sensitivity to the combined therapy.
Patricia D. Hurn, PhD, Guest Editor
Anesthesiology/Critical Care Medicine
Johns Hopkins Medical Institutions
Baltimore, Maryland
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